
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems is well positioned to sustain mid-single digit organic revenue growth and double-digit EPS growth because its Cardiovascular-led portfolio benefits from new product launches, acquisitions, pricing actions, and cost reduction efforts. The company is tracking to a roughly 6.6% organic revenue CAGR for 2024-2026, versus a 5%-7% target, while consensus implies a 2026 adjusted operating margin of 21.2% and cumulative free cash flow of $634M, both above the original CGI plan. With healthy U.S. and European demand, improving China trends, and early signs of a higher-growth therapeutic mix shift, its margin expansion and cash generation appear durable even amid tariff headwinds.
Bears say
Merit Medical Systems is facing a negative outlook because the forecast improvement in gross margin from 50.4% in 2023A to 54.0% in 2026E is being partly offset by rising SG&A to 27.0% of sales, leaving operating leverage dependent on execution that could disappoint. The bear case already assumes revenue growth of 5% or lower, driven by weaker acquisition growth and unsuccessful new product launches, which could trigger further margin contraction and below-consensus earnings. Although 1Q26 free cash flow improved to $25M and net leverage stayed at 1.6x, risks such as margin pressure, slower China growth, and acquisition integration remain significant.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares